Table 1

Description of LAIV recipients at enrolment: demographics and high-risk medical conditions

DescriptorSeason 2013–2014 (n=4718)Season 2014–2015 (n=6745)Total population (n=11 463)
Age, years
 2–322% (1033)12% (799)16% (1832)
 4–835% (1644)37% (2533)36% (4177)
 9–1743% (2041)51% (3413)48% (5454)
Gender
 Male58% (2722)58% (3893)58% (6615)
 Female42% (1996)42% (2852)42% (4848)
High-risk medical conditions*
 Asthma73% (3442)74% (5016)74% (8458)
 Cystic fibrosis1% (38)1% (47)1% (85)
 Congenital lung abnormalities<1% (15)<1% (23)<1% (38)
 Other chronic respiratory disease1% (36)1% (39)1% (75)
 Chronic heart disease13% (631)12% (799)12% (1430)
 Chronic renal disease2% (73)1% (88)1% (161)
 Sickle cell anaemia1% (62)1% (90)1% (152)
 White blood cell disorders<1% (15)<1% (24)<1% (39)
 Immunosuppressive disorders (excluding malignancy)1% (66)2% (119)2% (185)
 Malignancy2% (71)1% (95)1% (166)
 Diabetes mellitus4% (188)4% (304)4% (492)
 Lipid metabolism disorders<1% (1)<1% (7)<1% (8)
 Cerebral palsy3% (118)2% (137)2% (255)
 Down syndrome1% (63)1% (98)1% (161)
 Chronic liver disease<1% (7)<1% (8)<1% (15)
 Chronic neurological disease2% (106)2% (131)2% (237)
 Any medical condition chronically treated with aspirin<1% (18)<1% (18)<1% (36)
 Pregnancy<1% (1)<1% (1)<1% (2)
  • *Several high-risk medical conditions could be present at baseline.

  • LAIV, live attenuated influenza vaccine.